Achieve Life Sciences Appoints Benjamin Halladay as Chief Financial Officer
Achieve Life Sciences appointed Benjamin Halladay, CPA, as Chief Financial Officer effective October 5, 2026, succeeding Mark Oki, who steps down the same day. Halladay was CFO of Esperion Therapeutics from November 2022 to July 2026, where he led the finance workstream through Esperion's sale to ARCHIMED for up to $1.1 billion.
Key figures
- Esperion sale value
- up to $1.1 billion
- Esperion annual revenue
- $400 million
- Esperion acquisition premium
- 58%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.